- Home
- FDMT vs GHRS Comparison
FDMT vs GHRS Comparison
Compare FDMT & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- GHRS
- Stock Information
- Founded
- FDMT 2013
- GHRS 2018
- Country
- FDMT United States
- GHRS Ireland
- Employees
- FDMT N/A
- GHRS N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- FDMT Health Care
- GHRS Health Care
- Exchange
- FDMT Nasdaq
- GHRS Nasdaq
- Market Cap
- FDMT 420.7M
- GHRS 470.3M
- IPO Year
- FDMT 2020
- GHRS 2021
- Fundamental
- Price
- FDMT $8.21
- GHRS $10.53
- Analyst Decision
- FDMT Strong Buy
- GHRS Strong Buy
- Analyst Count
- FDMT 9
- GHRS 3
- Target Price
- FDMT $46.75
- GHRS $35.67
- AVG Volume (30 Days)
- FDMT 759.8K
- GHRS 66.9K
- Earning Date
- FDMT 11-13-2024
- GHRS 11-14-2024
- Dividend Yield
- FDMT N/A
- GHRS N/A
- EPS Growth
- FDMT N/A
- GHRS N/A
- EPS
- FDMT N/A
- GHRS N/A
- Revenue
- FDMT $17,000.00
- GHRS N/A
- Revenue This Year
- FDMT N/A
- GHRS N/A
- Revenue Next Year
- FDMT $57.85
- GHRS N/A
- P/E Ratio
- FDMT N/A
- GHRS N/A
- Revenue Growth
- FDMT N/A
- GHRS N/A
- 52 Week Low
- FDMT $7.32
- GHRS $5.05
- 52 Week High
- FDMT $36.25
- GHRS $14.99
- Technical
- Relative Strength Index (RSI)
- FDMT 41.01
- GHRS 79.00
- Support Level
- FDMT $8.04
- GHRS $8.50
- Resistance Level
- FDMT $8.96
- GHRS $11.09
- Average True Range (ATR)
- FDMT 0.59
- GHRS 0.82
- MACD
- FDMT 0.16
- GHRS 0.23
- Stochastic Oscillator
- FDMT 37.10
- GHRS 95.83
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.